---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-021233"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:58:08.715172+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MoonLake reports 24-week PsA data with ~60% ACR50; plans Phase 3 HS trials in Q2 2024

## Summary
- ARGO trial: ~60% ACR50 at week 24; ~40% ACR70; >80% PASI90; ~60% PASI100; low discontinuation ~5%.
- Composite responses: ACR50+PASI100 up to 52%, MDA up to 61%; sonelokimab outperformed adalimumab.
- Regulatory feedback from FDA/EMA supports Phase 3 HS program (VELA) enrolling 800 patients; top-line data expected mid-2025.
- US real-world data: 2M diagnosed HS patients; market opportunity >$10B by 2035; low biologic penetration ~3%.
- Four additional clinical trials imminent in new indications (palmo-plantar pustulosis, juvenile HS, seronegative SpA).

## SEC filing metadata
- accession: 0001213900-24-021233
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390024021233/0001213900-24-021233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390024021233/ea0201498-8k_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-021233
- JSON: https://secwatch.observer/filing/0001213900-24-021233.json
- Plain text: https://secwatch.observer/filing/0001213900-24-021233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.